NASDAQ:BIOT Biotech Acquisition (BIOT) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free BIOT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.14▼$10.1950-Day Range$10.08▼$10.3252-Week Range$8.30▼$10.41Volume44,400 shsAverage Volume244,605 shsMarket Capitalization$291.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biotech Acquisition alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Biotech Acquisition Stock (NASDAQ:BIOT)Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. BIOT Stock News HeadlinesApril 26, 2024 | msn.comEli Lilly’s acquisition of Nexus facility marks a new era for Pleasant Prairie’s pharmaceutical landscapeApril 26, 2024 | finanznachrichten.deSagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 26, 2024 | markets.businessinsider.comBuy Rating on Danaher: Strong Biotech Performance and Growth Potential Despite Market ChallengesApril 26, 2024 | msn.comPhiladelphia-based Century Therapeutics Acquires Boston Biotechnology Firm Clade TherapeuticsApril 25, 2024 | msn.comImproved US biotech funding to aid FY25 growth, expects Jonathan Hunt, MD & CEO, Syngene InternationalApril 24, 2024 | msn.comPharmaceutical giant Bayer’s manager cull will likely affect thousands of bosses—and the aspirin inventor thinks it will help its ‘brilliant’ Gen Z grads to thriveApril 24, 2024 | finance.yahoo.comIMCD Spain expands its Pharmaceuticals presence with the acquisition of CobapharmaApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.April 22, 2024 | msn.comMBK Partners acquires pharmaceutical wholesaler Geo-Young from BlackstoneApril 19, 2024 | bizjournals.comSpark co-founder, Harvard professor launch Watertown biotech with $54MApril 19, 2024 | seekingalpha.comXBI: 3 Reasons To Buy The Pullback And Hold This Biotech ETF ForeverApril 18, 2024 | msn.comSan Diego biotech company making melanoma test patch cuts 56% of its workforceApril 18, 2024 | finance.yahoo.comStramsen Biotech Joins Elite Class of Unicorns at $6.5 Billion Valuation and a Potential Reverse Merger DealApril 17, 2024 | finance.yahoo.comEssential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral CapsulesApril 16, 2024 | finance.yahoo.comPharmAlliance Announces Acquisition of CHEORSApril 15, 2024 | finance.yahoo.comGlobal Directory Unveils Top 1,000 Pharmaceutical and Biotechnology Companies for 2024April 12, 2024 | bizjournals.comEliem pursues acquisition of New Jersey biotech after halting programsApril 11, 2024 | finance.yahoo.comVertex Pharmaceuticals Incorporated: Vertex: $4.9 Billion Acquisition of Alpine Immune Sciences Expands Kidney-Disease PortfolioApril 10, 2024 | marketwatch.comVera Therapeutics Shares Rise 9.9% After Alpine AcquisitionApril 10, 2024 | bizjournals.comVertex to acquire Seattle biotech for $4.9BApril 10, 2024 | msn.comVertex buying Seattle biotech for $4.9 billion, its biggest acquisition everApril 8, 2024 | bizjournals.comBiotech layoffs tracker: 14 biotechs cut over 300 jobs in Q1 2024April 6, 2024 | finance.yahoo.com2 Biotech Stocks to Buy Hand Over Fist in AprilApril 5, 2024 | finance.yahoo.comJohnson & Johnson: J&J: Shockwave Acquisition Adds Fast-Growing Medical DevicesApril 4, 2024 | msn.comBristol Myers Squibb to lay off hundreds of workers following its $4.8B merger with this San Diego biotechApril 4, 2024 | markets.businessinsider.comMitsui & Co., ROHTO Pharmaceutical To Acquire Shares In Eu Yan Sang InternationalSee More Headlines Receive BIOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotech Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BIOT CUSIPN/A CIK1825413 Webbioacq.com Phone212-227-1905FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.22% Return on Assets3.48% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.95) per share Price / Book-10.68Miscellaneous Outstanding Shares28,750,000Free Float23,288,000Market Cap$291.81 million OptionableNot Optionable Beta-0.12 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Michael Shleifer Ph.D. (Age 48)Chairman & CEO Mr. Thomas Fratacci (Age 44)CFO & Treasurer Mr. Ivan Jarry (Age 44)Chief Operating Officer Mr. Albert F. Hummel M.B.A. (Age 76)Chief Investment Officer & Director Key CompetitorsSilverback TherapeuticsNASDAQ:SBTXContineum TherapeuticsNASDAQ:CTNMXOMANASDAQ:XOMAAquestive TherapeuticsNASDAQ:AQSTVentyx BiosciencesNASDAQ:VTYXView All Competitors This page (NASDAQ:BIOT) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotech Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
